Enhanced usability to support PCR applications in basic and translational research, process development, and quality control
Services support peptide purification, custom synthesis of PEC-grade peptides, and development and production of peptide drugs and drug candidates PurePep® EasyClean (PEC) orthogonal purification technology for peptide purification now fully integrated into Company’s kits and services offerings
But only a small number of cases were found suggesting pets are not a major source of antibiotic-resistant infections in hospital patients
Clario has partnered with Strados Labs to offer its customers the RESP™ Biosensor System, an advanced technological innovation for the at-home capture of lung sounds. The revolutionary device enables Clario to support the capture of additional clinical respiratory endpoints such as cough and wheeze, and it does so in a patient-friendly, streamlined way.
INTEGRA Biosciences is delighted to announce that it has acquired Miroculus, a biotechnology specialist focused on developing hands-off automation solutions for next generation sequencing (NGS) protocols. This will allow INTEGRA to expand its product range for library preparation, offering significant time savings to academic, research and diagnostics laboratories using NGS and, ultimately, accelerating discovery in […]
QuantaMatrix’s direct Rapid Antimicrobial Susceptibility Testing system (dRAST™) improves optimal prescription of antibiotics by two days compared to conventional methods – thanks to gram-negative and gram-positive sepsis-causing bacteria panels Follows successful adoption of dRAST solution in routine clinical use in clinical laboratories in Europe and Asia
Research will focus on applying Bicycle’s bicyclic peptide technology to Owlstone’s EVOC Probes Antigen-targeted EVOC Probes have potential for use in preclinical research, clinical trials, and as companion diagnostics and tests for early detection of disease Initial research will focus on the early detection of lung cancer
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that, following positive results in the lead-in phase of the clinical phase Ib/II trial TRIFOUR, the first triple-negative breast cancer (TNBC) patient has initiated treatment with the IL1RAP-binding antibody nadunolimab (CAN04) and chemotherapy in the phase II randomized part of the trial. Up to 98 patients may […]
The biotechnology company Neogap and the cancer diagnostics company Simsen Diagnostics have initiated a collaboration aimed at improving personalised cancer diagnostics by examining circulating tumor DNA in the blood of patients participating in Neogap’s phase I/II clinical trial. The goal is to develop more precise and effective diagnostic tools for cancer.
Building on a 25+ year partnership, the companies will each provide one of the largest hemostasis testing system and reagent portfolios to laboratories. Under the multi-year agreement, both companies will individually distribute their combined portfolio of hemostasis instruments and reagents worldwide under their respective own brands.
November 2025
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.